List of Excipients in Branded Drug OZOBAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	ANHYDROUS CITRIC ACID
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	GLYCERIN
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	METHYLPARABEN
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	PROPYLPARABEN
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	SUCRALOSE
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	TRISODIUM CITRATE DIHYDRATE
Metacel Pharmaceuticals LLC	OZOBAX	baclofen	69528-301	WATER

Ozobax Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Ozobax is an FDA-approved baclofen oral solution containing 5 mg of baclofen per 5 mL. Its commercial differentiation is primarily the liquid dosage form, not molecular exclusivity. The largest excipient opportunities are improved taste, preservative reduction, dose-concentration flexibility, enteral-tube performance, and pediatric usability. Generic and follow-on entrants face a relatively modest formulation barrier because baclofen is an established small molecule and the marketed product is an immediate-release oral solution.

What is Ozobax and which excipients does it contain?

Ozobax is an oral solution of baclofen, a gamma-aminobutyric acid type B receptor agonist used for the treatment of spasticity. The labeled strength is 5 mg/5 mL, equivalent to 1 mg/mL.[1]

The FDA-approved product uses a conventional aqueous liquid architecture. The U.S. prescribing information identifies inactive ingredients that include sweetening agents, preservatives, buffering or pH-control components, water, and flavoring materials.[1,2]

Component category	Ozobax strategy	Commercial function
Vehicle	Purified aqueous vehicle	Dissolves baclofen and supports oral dosing
Sweeteners	Sorbitol and sucralose are identified in product information	Reduces bitterness and supports sugar-free positioning
Humectant or solvent	Glycerin is identified in product information	Improves mouthfeel and helps solubilization
Preservatives	Methylparaben and propylparaben are identified	Supports multidose microbial control
Buffer or pH control	Citric acid and sodium citrate are associated with the formulation	Maintains chemical stability and palatability
Flavor	Product flavor system	Masks baclofen bitterness and improves adherence
Water	Purified water	Primary liquid vehicle

The precise quantitative composition and manufacturing process are not fully disclosed in the public prescribing information. Those parameters can determine whether a competing product achieves pharmaceutical equivalence, comparable stability, and acceptable taste.

What formulation problems does baclofen create?

Baclofen presents several formulation challenges that make excipient selection commercially relevant.

Bitter taste and pediatric acceptability

Baclofen has a bitter taste that can impair adherence, especially in children and patients requiring chronic treatment. Increasing sweetener concentration alone may not solve the problem. High-intensity sweeteners can produce lingering aftertaste, while polyols can affect mouthfeel and gastrointestinal tolerance.

A competitive formulation may combine:

• A bitterness suppressant
• A high-intensity sweetener
• A polyol or humectant
• A fruit or confectionary flavor
• A pH adjustment strategy
• A physical or chemical taste-masking system

A taste-masking package supported by validated sensory data could create a meaningful commercial advantage even if the active ingredient and concentration remain unchanged.

Preservative exposure

Multidose oral solutions generally require antimicrobial protection unless the product uses a preservative-free delivery system. Ozobax uses parabens according to its labeling.[1]

A reformulator could pursue:

• Lower total preservative concentration
• Alternative preservative systems
• Preservative-free unit-dose packaging
• Aseptic or low-bioburden manufacturing
• Single-use oral syringes or sachets

Preservative reduction may have commercial value in pediatric, long-term-care, and chronic neurological treatment settings. A preservative-free product would require a stronger package, including container-closure validation, microbial challenge testing, in-use stability, and a credible manufacturing-control strategy.

Dose measurement

At 1 mg/mL, a 5 mL dose contains 5 mg of baclofen. Patients requiring higher doses must administer larger volumes. This can create adherence and administration problems.

Potential alternatives include:

Product concept	Potential benefit	Main barrier
2 mg/mL oral solution	Reduces administration volume	Higher concentration may affect solubility, taste, and stability
5 mg/5 mL standard solution	Direct competition with Ozobax	Requires strong taste and price differentiation
Unit-dose oral syringe	Reduces measurement error	Packaging and supply-chain cost
Concentrated multidose solution	Supports high-dose adult use	Greater risk of dosing errors
Pediatric low-volume product	Improves administration in small children	Requires careful dosing and labeling
Ready-to-administer sachet	Convenient home and institutional use	Higher packaging cost

A concentrated product has the greatest commercial upside but also the highest medication-error risk. FDA labeling would need to make the concentration and measuring device unambiguous.

What commercial opportunities exist for Ozobax excipients?

The most defensible opportunities are incremental improvements that solve administration problems without changing the therapeutic role of baclofen.

1. Improved taste-masking system

A taste-optimized product could target pediatric neurology, rehabilitation, specialty pharmacies, and caregivers administering chronic medication at home.

Potential technologies include:

• Ion-exchange resin complexes
• Cyclodextrin complexes
• Polymer-based taste barriers
• Lipid or emulsion systems
• Microencapsulation
• Flavor modulation using acidic or fruit profiles

The key commercial test is whether the technology maintains rapid release after swallowing. A formulation that delays or reduces baclofen release could create bioequivalence and clinical-performance problems.

2. Preservative-free unit-dose presentation

A preservative-free product could compete on tolerability and institutional convenience. Unit-dose oral syringes could reduce contamination risk and eliminate repeated bottle opening.

The opportunity is strongest in:

• Pediatric hospitals
• Long-term-care facilities
• Home nursing
• Hospice and palliative care
• Patients with excipient sensitivity
• Institutions seeking ready-to-administer medications

The disadvantage is cost. Preservative-free packaging can increase manufacturing, inspection, labeling, and distribution expenses. A premium price would require a clear operational benefit.

3. Excipient-minimized formulation

A simplified formulation could remove avoidable excipients, reduce allergen concerns, and support use in patients with dietary or intolerance restrictions.

Potential positioning includes:

• Sugar-free
• Alcohol-free
• Dye-free
• Gluten-free, where substantiated
• Reduced-excipient
• Paraben-free
• Low-osmolality

Marketing claims must be supported by formulation records, supplier controls, analytical testing, and applicable FDA requirements. "Sugar-free" and "paraben-free" claims are commercially useful only if the formulation and label consistently support them.

4. Enteral-tube compatibility

Baclofen is used in patients with severe neurological impairment who may rely on feeding tubes. A product that demonstrates compatibility with common enteral tubes could gain institutional adoption.

The development package should assess:

• Dose recovery after tube delivery
• Adsorption to tubing
• Clumping or precipitation
• Rinse-volume requirements
• Compatibility with enteral nutrition
• Tube material effects
• Stability after transfer to an oral syringe
• Risk of obstruction

Enteral-tube data would be especially valuable if presented in standardized administration instructions. This opportunity is more likely to support physician and hospital preference than broad consumer differentiation.

What FDA pathway applies to an Ozobax follow-on product?

A follow-on baclofen oral solution could potentially use an ANDA under section 505(j) if it demonstrates pharmaceutical equivalence and bioequivalence to the applicable reference product. The applicant would need to address the active ingredient, strength, dosage form, route, labeling, quality attributes, and inactive ingredients.[3]

A materially different formulation may require a 505(b)(2) application. This could apply where the product introduces:

• A new concentration
• A different delivery system
• A novel taste-masking technology
• A different preservative architecture
• A new dosage device
• A clinically meaningful excipient change
• A new route or administration method

The regulatory route depends on the product's differences and the extent to which the applicant relies on FDA findings for an approved product. An ANDA generally provides a more efficient route, but it limits formulation freedom. A 505(b)(2) application provides greater flexibility but may require additional studies and expose the applicant to listed-patent certifications.

What excipient changes are allowed in an ANDA?

FDA permits certain differences in inactive ingredients when the applicant provides adequate justification and the change does not affect safety or performance. Changes are more difficult when they involve:

• Novel excipients
• Higher levels of excipients associated with toxicity
• Pediatric-use concerns
• Different preservatives
• Different sweetener systems
• Excipients that affect absorption
• Components that change viscosity or dose delivery

A generic solution with the same inactive ingredients in the same amounts has the lowest regulatory risk. A product with a differentiated excipient system may require a more substantial equivalence argument.

What patents protect Ozobax and its formulation?

Publicly available FDA product information identifies Ozobax as baclofen oral solution, NDA 209881.[1,2] The principal commercial barrier is the approved product and its formulation know-how rather than baclofen composition-of-matter protection.

A complete freedom-to-operate review should examine:

1. U.S. patents listed for NDA 209881 in the FDA Orange Book.
2. Formulation patents covering baclofen solutions.
3. Taste-masking and preservative-system patents.
4. Packaging patents covering prefilled oral syringes or unit-dose containers.
5. Manufacturing-process patents.
6. Continuation and divisional applications.
7. Patent term adjustment and terminal disclaimers.
8. Patent families in the United States, Europe, Japan, China, and other target markets.

The Orange Book is the controlling public source for patents submitted for listing against an approved drug application.[4] A formulation patent not listed in the Orange Book may still create litigation or licensing risk, particularly for a 505(b)(2) product.

How strong is the Ozobax patent estate?

The apparent patent strength is lower than that of a new chemical entity with active composition-of-matter claims. Baclofen is an old active ingredient, and tablets and other dosage forms are widely available.

The potentially stronger areas are:

• Specific excipient ratios
• pH and preservative combinations
• Stability under defined storage conditions
• Taste-masking systems
• Concentrated solutions
• Device-linked dosing systems
• Manufacturing controls that produce a defined impurity profile

These claims are vulnerable if earlier baclofen solutions, compounded formulations, or analogous oral-liquid technologies disclose the same elements. A formulation patent would be strongest when it links a narrow composition to unexpected stability, improved palatability, reduced degradation, or a clinically relevant administration benefit.

When does Ozobax lose exclusivity?

Ozobax does not have the exclusivity profile of a recently launched innovative drug. Baclofen has long-standing generic tablet competition, and the commercial opportunity is confined largely to the liquid formulation.

Exclusivity element	Ozobax assessment
Active ingredient exclusivity	Not applicable in practical terms; baclofen is an established generic active
Dosage-form differentiation	Oral solution is the principal product distinction
FDA approval	Ozobax received FDA approval under NDA 209881; public product materials identify the marketed strength as 5 mg/5 mL
Regulatory exclusivity	Any exclusivity would depend on the specific approval and FDA records
Orange Book patents	Must be confirmed against the current FDA listing for NDA 209881
Generic entry	Most plausible through an ANDA for baclofen oral solution
505(b)(2) competition	Possible for differentiated concentration, device, or formulation

A specific generic launch date cannot be inferred solely from the brand name. It depends on FDA approval timing, Paragraph IV litigation, settlement terms, regulatory exclusivity, and any enforceable listed or unlisted patents.

Which companies are challenging Ozobax?

The competitive field includes manufacturers of generic baclofen tablets and potential developers of baclofen oral solution products. A tablet is not a direct pharmaceutical substitute for an oral solution in every patient, but it limits the price ceiling because prescribers can use an established low-cost baclofen dosage form.

Relevant competitive groups include:

• Generic tablet manufacturers
• Specialty pharmaceutical companies developing oral liquids
• Compounding pharmacies
• Contract manufacturers with oral-liquid capability
• Pediatric and hospital-focused drug companies
• Packaging suppliers offering unit-dose oral syringes

No definitive Paragraph IV challenger or settlement agreement should be attributed without a current FDA Orange Book review, ANDA litigation search, and PACER docket analysis.

What litigation and settlement risks affect Ozobax?

Potential litigation would most likely involve formulation, method-of-use, manufacturing, or device claims rather than baclofen's active ingredient.

Paragraph IV risk

An ANDA applicant could certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. A timely notice letter could trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[5]

The most likely dispute areas are:

• Whether the generic solution practices a claimed excipient combination
• Whether a preservative or pH range falls within a patent claim
• Whether a dosing device is covered
• Whether the proposed labeling induces infringement of a method-of-use claim
• Whether the formulation is independently developed or copied

Settlement agreements

A settlement could establish an agreed generic entry date, license terms, or permitted formulation restrictions. Any agreement involving a branded or generic company may be subject to FTC review and federal reporting requirements under applicable law.[6]

The commercial value of a settlement depends on whether the generic can launch with the same concentration and presentation or must wait for a later formulation change.

What method-of-use patents could affect baclofen oral solution?

Method-of-use protection is more limited than formulation protection for an established drug. Potential claims may relate to:

• Treatment of specific spasticity populations
• Pediatric dosing
• Titration schedules
• Administration through feeding tubes
• Combination therapy
• Use in patients unable to swallow tablets

A method-of-use patent matters only if the generic label includes the patented indication or instructions, or if the branded company can establish induced infringement. Carve-out labeling can reduce risk where the FDA-approved indications permit omission of a patented use.

How does Ozobax compare with baclofen tablets and compounded solutions?

Criterion	Ozobax oral solution	Generic baclofen tablets	Compounded baclofen liquid
FDA-approved finished product	Yes	Yes	Generally no product-specific FDA approval
Dose flexibility	High	Lower without splitting or multiple units	High
Preservative control	Defined commercial formulation	Not applicable to tablet	Varies by pharmacy
Quality consistency	Manufacturer-controlled	Manufacturer-controlled	Depends on compounding practice
Pediatric administration	More practical	Often difficult	Practical but variable
Price pressure	Moderate to high	Very high	Variable
Patent exposure	Formulation and device dependent	Low for active ingredient	Usually low, but not zero
Institutional documentation	Standardized label	Standardized label	Pharmacy-specific

Ozobax's most defensible value proposition is convenience and quality consistency for patients who cannot reliably use tablets. Its weakest commercial position is price competition against generic tablets and pharmacy-compounded liquids.

What geographic opportunities exist?

The highest-value markets are those with strong demand for pediatric medicines, home administration, and specialty oral liquids.

United States

The U.S. opportunity is the most developed because Ozobax is FDA approved and the Orange Book and ANDA framework create a defined regulatory pathway. Hospital formularies, specialty pharmacies, and pediatric neurology are key channels.

Europe

European opportunities depend on national authorization, mutual-recognition or decentralized procedures, local reimbursement, and country-specific rules for pediatric formulations. A U.S. formulation patent does not automatically provide European protection.

Emerging markets

Markets with limited access to pediatric liquids may favor lower-cost local production or licensing. The principal barriers are:

• Stability under high-temperature conditions
• Packaging quality
• Reliable preservative performance
• Local registration
• Supply-chain control
• Counterfeit resistance

A heat-stable, low-cost formulation in unit-dose packaging could have licensing value where imported branded products are too expensive.

What manufacturing and intellectual-property barriers matter?

The technical barriers are manageable but not trivial. A commercial entrant must control:

• Baclofen assay and impurity profile
• pH drift
• Preservative effectiveness
• Microbial limits
• Flavor uniformity
• Viscosity
• Fill-volume accuracy
• Container compatibility
• Extractables and leachables
• In-use stability
• Dose-device performance

Excipient suppliers can create additional differentiation through proprietary flavor systems, preservative blends, polymers, or taste-masking materials. A supplier's patent may restrict direct copying even when the finished-drug applicant has no patent on the overall product.

The strongest IP strategy would combine a narrow formulation patent with trade secrets covering mixing order, temperature control, flavor incorporation, preservative dispersion, and packaging-fill conditions. Process claims are most valuable when they produce measurable product attributes that competitors cannot easily avoid.

What is the revenue exposure and commercial outlook?

Ozobax revenue is exposed to three forces:

1. Generic price competition from baclofen tablets.
2. Potential ANDA entry for the same oral-solution strength.
3. Substitution by compounding pharmacies and alternative oral-liquid products.

Revenue protection depends on whether the manufacturer can preserve a premium for FDA-approved liquid quality, pediatric usability, and supply reliability. Excipient innovation can support that premium, but it is unlikely to create a durable high-value franchise without a protected device, a differentiated concentration, or strong clinical-use data.

The most commercially attractive development sequence is:

1. Optimize taste and mouthfeel.
2. Validate enteral-tube delivery.
3. Develop a preservative-free unit-dose presentation.
4. Assess a 2 mg/mL or other reduced-volume concentration.
5. Protect the formulation and dosing system with composition, use, and device claims.
6. Select an ANDA or 505(b)(2) strategy based on the degree of differentiation.

Key Takeaways

• Ozobax is baclofen oral solution at 5 mg/5 mL, or 1 mg/mL.
• Its commercial value comes from liquid administration, not active-ingredient exclusivity.
• The principal excipient opportunities are taste masking, preservative reduction, unit-dose packaging, and enteral-tube compatibility.
• A same-strength generic oral solution would likely create the most direct pricing pressure.
• A concentrated or preservative-free product could obtain stronger differentiation but would face greater regulatory and dosing risks.
• Formulation, device, manufacturing, and trade-secret protection are more relevant than composition-of-matter patents.
• An Orange Book, patent-family, and litigation review is essential before assigning a definitive generic-entry date or patent expiration date.

FAQs

Is Ozobax sugar-free?

Ozobax's public product information identifies sorbitol and sucralose rather than sucrose as sweetening components.[1,2] Commercial claims should follow the current approved labeling and formulation records.

Can baclofen oral solution be administered through a feeding tube?

Baclofen liquids may be administered through enteral tubes, but product-specific recovery, compatibility, and flushing instructions should be established before making a commercial or labeling claim.

Would a preservative-free Ozobax competitor require a new FDA application?

The regulatory pathway would depend on the extent of the formulation and packaging changes. A same-product ANDA may be possible with adequate inactive-ingredient justification, while a materially differentiated formulation or device could require a 505(b)(2) application.

Is a compounded baclofen liquid therapeutically equivalent to Ozobax?

A compounded preparation is not automatically therapeutically equivalent to an FDA-approved baclofen oral solution. Quality, stability, concentration, preservative performance, and labeling may differ.

Can excipients create patent protection for a baclofen oral solution?

Yes. A novel and nonobvious excipient combination, concentration range, taste-masking system, packaging system, or manufacturing process may support patent claims. The claims must survive prior-art and obviousness scrutiny.

References

1. U.S. Food and Drug Administration. (n.d.). Ozobax (baclofen) oral solution prescribing information, NDA 209881.

2. National Library of Medicine. (n.d.). DailyMed: Ozobax baclofen solution. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format of an ANDA. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.

6. Federal Trade Commission. (n.d.). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act. FTC.